Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Receivables (2021 - 2025)

Historic Receivables for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $259.0 million.

  • Indivior Pharmaceuticals' Receivables rose 318.73% to $259.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.0 million, marking a year-over-year increase of 318.73%. This contributed to the annual value of $256.0 million for FY2024, which is 39.22% up from last year.
  • Indivior Pharmaceuticals' Receivables amounted to $259.0 million in Q3 2025, which was up 318.73% from $240.0 million recorded in Q2 2025.
  • Indivior Pharmaceuticals' Receivables' 5-year high stood at $259.0 million during Q2 2024, with a 5-year trough of $202.0 million in Q4 2021.
  • For the 5-year period, Indivior Pharmaceuticals' Receivables averaged around $242.3 million, with its median value being $247.0 million (2023).
  • In the last 5 years, Indivior Pharmaceuticals' Receivables surged by 1590.91% in 2023 and then crashed by 733.59% in 2025.
  • Indivior Pharmaceuticals' Receivables (Quarter) stood at $202.0 million in 2021, then increased by 8.91% to $220.0 million in 2022, then increased by 15.91% to $255.0 million in 2023, then increased by 0.39% to $256.0 million in 2024, then increased by 1.17% to $259.0 million in 2025.
  • Its last three reported values are $259.0 million in Q3 2025, $240.0 million for Q2 2025, and $243.0 million during Q1 2025.